Thanks for this information. I saw the $20.4 million number in the company's press release, stating that this total was for the 4 months since acquisition. That obviously would translate to over $60 million p/a if sales stayed flat. Considering the expanded sales force and the company's focus on these 2 drugs, it would be a surprise if that happened. I'd like to know where you found this information, though. I can't find a 10-Q posted yet for the quarter and if product sales are broken out in the 8-K I can't seem to find the right page. TIA.
27M shorts don't like the current facts. And the facts are that they are screwed. Strong Folotyn sales hurt their argument that SPPI is a one trick pony that is destined for failure. Pretty pathetic that all they can do is hit the thumbs down and watch as time runs out for them.